Skip to contentH
Heron Therapeutics, Inc.
H
HRTXHeron Therapeutics, Inc. Q2 2017 · 10-Q
Revenue$8.51M$8.51Mno prior Q2 2016 on file Net Income-$42.80M-$42.80MN/M vs Q2 2016 EPS Diluted-$0.80-$0.80N/M vs Q2 2016 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Heron Therapeutics, Inc. · CIK 818033 · Engraved from SEC EDGAR
Operating Cash Flowderived-$32,030,000N/M Free Cash Flowderived-$32,516,000N/M Margins · derivedGross margin88.1%
Operating margin-494.2%
Net margin-502.9%
ended Jun 30, 2017 · filed Aug 9, 2017 · 40 d after period end